EAN 2024 | Therapeutic hypothermia plus melatonin in neonates with hypoxic ischemic encephalopathy

Maria Roberta Cilio, MD, PhD, Université Catholique de Louvain, Brussels, Belgium, describes the use of therapeutic hypothermia as a neuroprotective strategy in the treatment of hypoxic ischemic encephalopathy, the most common cause of neonatal seizures. She goes onto explain new developments in therapies such as ‘hypothermia plus’, with an emphasis on trials for the use of melatonin. Therapeutic hypothermia plus melatonin shows promise as an additional treatment that can be given to patients outside of the normal treatment window for therapeutic hypothermia. Moreover, it could be given for more severe cases of hypoxic ischemic injury.
This interview took place at the European Academy of Neurology (EAN) Annual Meeting 2024 in Helsinki, Finland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.